Viewing Study NCT04224493


Ignite Creation Date: 2025-12-25 @ 1:10 AM
Ignite Modification Date: 2025-12-25 @ 11:21 PM
Study NCT ID: NCT04224493
Status: RECRUITING
Last Update Posted: 2025-12-16
First Post: 2019-12-12
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
Sponsor: Epizyme, Inc.
Organization:

Key Dates - Follows AllAPIJSON File Order

Start Date: 2020-06-11
Start Date Type: ACTUAL
Primary Completion Date: 2026-03-01
Primary Completion Date Type: ESTIMATED
Completion Date: 2029-03-01
Completion Date Type: ESTIMATED
First Submit Date: 2019-12-12
First Submit QC Date: None
Study First Post Date: 2020-01-13
Study First Post Date Type: ACTUAL
Results First Submit Date: None
Results First Submit QC Date: None
Results First Post Date: None
Results First Post Date Type: None
Results First Post QC Date: None
Results First Post QC Date Type: None
Disp First Submit Date: None
Disp First Submit QC Date: None
Disp First Post Date: None
Disp First Post Date Type: None
Last Update Submit Date: 2025-12-10
Last Update Post Date: 2025-12-16
Last Update Post Date Type: ESTIMATED